Skip to content

Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Arena Pharmaceuticals Provides Corporate Update and Reports First Quarter 2018 Financial Results
- Achieved positive Phase 2 results for etrasimod in ulcerative colitis in March; Phase 3 preparations for ulcerative colitis and a development plan for Crohn's disease underway - Expect to initiate Phase 3 studies for ralinepag in pulmonary arterial hypertension in second half of 2018 SAN DIEGO ,
View HTML
Toggle Summary Arena Pharmaceuticals to Release First Quarter 2018 Financial Results and Provide Corporate Update on Tuesday, May 8
SAN DIEGO , May 2, 2018 /PRNewswire/ --  Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that the Company will release its first quarter 2018 financial results and provide a corporate update on Tuesday, May 8, 2018 , after the close of the U.S.
View HTML
Toggle Summary Arena Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full-Year 2017 Financial Results
- Etrasimod Phase 2 Data in UC Anticipated this Month - Ralinepag Phase 3 Clinical Program Expected to Begin in H2 2018 SAN DIEGO , March 14, 2018 /PRNewswire/ --  Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), today provided a corporate update and reported financial results for the fourth quarter and
View HTML
Toggle Summary Arena Pharmaceuticals to Announce Fourth Quarter and Full-Year 2017 Financial Results and Provide Corporate Update on Wednesday, March 14
SAN DIEGO , March 8, 2018 /PRNewswire/ --  Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), will announce its fourth quarter and full-year 2017 financial results on Wednesday, March 14, 2018 , before the open of the U.S. financial markets.  The Company will host a conference call and live webcast to
View HTML
Toggle Summary Arena Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2017 Financial Results
- Submitted Ralinepag FDA Meeting Request<br>- Expect to Complete Full Enrollment for Etrasimod Phase 2 Study in Ulcerative Colitis This Week<br>- Initiated Etrasimod Phase 2 Study in Primary Biliary Cholangitis
View HTML
Toggle Summary Arena Pharmaceuticals to Release Third Quarter 2017 Financial Results and Provide Corporate Update on Tuesday, November 7
SAN DIEGO , Oct. 30, 2017 /PRNewswire/ --  Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), today announced that the Company will release its third quarter 2017 financial results and provide a corporate update on Tuesday, November 7, 2017 , after the close of the U.S.
View HTML
Toggle Summary Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2017 Financial Results
- Achieved Positive Phase 2 Results for Ralinepag in July, Phase 3 Preparations Underway<br>- Clinical Results from Additional Phase 2 Programs Expected Over the Next Several Quarters
View HTML
Toggle Summary Arena Pharmaceuticals to Release Second Quarter 2017 Financial Results and Provide Corporate Update on Monday, August 7, 2017
SAN DIEGO , July 31, 2017 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), today announced that the Company will release its second quarter 2017 financial results and provide a corporate update on Monday, August 7, 2017 , after the close of the U.S.
View HTML
Toggle Summary Arena Pharmaceuticals Provides Corporate Update and Reports First Quarter 2017 Financial Results
- Clinical Data from Multiple Phase 2 Development Programs Expected in 2017 -<br>- Ralinepag Phase 2 Study Results Expected in July -
View HTML
Toggle Summary Arena Pharmaceuticals to Release First Quarter 2017 Financial Results and Provide Corporate Update on Tuesday, May 9, 2017
SAN DIEGO , May 2, 2017 /PRNewswire/ --  Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), a biopharmaceutical company focused on developing novel, small molecule drugs across multiple therapeutic areas, today announced that the Company will release its first quarter 2017 financial results and provide a
View HTML